Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 8/20 | 0.55 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.51 |
| ▸ | NTSR1 | P30989 | 2/20 | 0.51 |
| ▸ | CALCR | P30988 | 3/20 | 0.51 |
| ▸ | NTSR2 | O95665 | 1/20 | 0.50 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.49 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.49 |
| ▸ | F2 | P00734 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31679438 | 0.95 | AGTR2 (0.53) | OPRD1NTSR1NTSR2AGTR1AGTR2 | |
| SCHEMBL31679348 | 0.93 | AGTR2 (0.54) | OPRD1NTSR1NTSR2AGTR1AGTR2 | |
| SCHEMBL31679433 | 0.93 | NTSR1 (0.54) | OPRD1OPRM1NTSR1NTSR2AGTR1 | |
| SCHEMBL31679352 | 0.93 | AGTR2 (0.52) | OPRD1NTSR1NTSR2AGTR1AGTR2 | |
| SCHEMBL31679341 | 0.92 | AGTR2 (0.52) | OPRD1NTSR1NTSR2AGTR1AGTR2 | |
| SCHEMBL31679360 | 0.91 | OPRD1 (0.55) | OPRD1OPRM1NTSR1NTSR2AGTR1 | |
| SCHEMBL31679423 | 0.91 | AGTR2 (0.51) | OPRD1NTSR1NTSR2AGTR1AGTR2 | |
| SCHEMBL31679422 | 0.90 | AGTR2 (0.52) | OPRD1NTSR1NTSR2AGTR1AGTR2 | |
| SCHEMBL31679384 | 0.90 | NTSR1 (0.52) | NTSR1NTSR2AGTR1AGTR2F2 | |
| SCHEMBL31679451 | 0.90 | AGTR2 (0.52) | OPRD1NTSR1NTSR2AGTR1AGTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4610269-A1 | UROKINASE PLASMINOGEN ACTIVATOR SURFACE RECEPTOR (UPAR) LIGANDS FOR DIAGNOSTIC OR THERAPEUTIC USE | 3B Pharmaceuticals GmbH (DE) | 2025-09-03 | — | — | EP | disclosed |